A detailed history of Dn B Asset Management As transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Dn B Asset Management As holds 2,353 shares of KRYS stock, worth $437,799. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,353
Previous 2,300 2.3%
Holding current value
$437,799
Previous $409,000 5.62%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 05, 2024

BUY
$153.12 - $183.64 $8,115 - $9,732
53 Added 2.3%
2,353 $432,000
Q1 2024

Apr 12, 2024

BUY
$108.01 - $179.35 $248,423 - $412,505
2,300 New
2,300 $409,000
Q2 2022

Jul 08, 2022

SELL
$48.93 - $73.47 $1.2 Million - $1.8 Million
-24,500 Closed
0 $0
Q1 2022

Apr 08, 2022

SELL
$51.99 - $72.11 $579,168 - $803,305
-11,140 Reduced 31.26%
24,500 $1.63 Million
Q4 2021

Jan 12, 2022

BUY
$39.81 - $88.24 $1.42 Million - $3.14 Million
35,640 New
35,640 $2.49 Million

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.78B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Dn B Asset Management As Portfolio

Follow Dn B Asset Management As and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

News

Stay updated on Dn B Asset Management As with notifications on news.